Home Blog Page 567

LGHL ANNOUNCES THAT ITS WHOLLY-OWNED SUBSIDIARY HAS BEEN GRANTED EXCLUSIVITY TO FURTHER NEGOTIATIONS AND THE ENTERING INTO OF A FORMAL AGREEMENT IN RESPECT OF THE PROPOSED RESTRUCTURING OF SKYFAME REALTY (HOLDINGS) LIMITED (IN LIQUIDATION)

By
Advertorial Desk
-

SINGAPORE, April 14, 2026 /PRNewswire/ — Lion Group Holding Ltd. (the “Company” or “LGHL”) is pleased to announce that its wholly-owned subsidiary, Lion Wealth Management Limited (“Lion Wealth”), has entered into an exclusivity agreement dated April 10, 2026 with Skyfame Realty (Holdings) Limited (In Liquidation) (“Skyfame”, stock code: 00059.HK) and its joint provisional liquidators.

Under the Exclusivity Agreement, Lion Wealth has been granted the exclusivity to further negotiations and the entering into of a formal agreement with Skyfame in respect of the proposed restructuring and resumption of trading on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”). The Exclusivity Agreement does not constitute any binding obligation or commitment on the parties to enter into any transaction or be bound by any terms and conditions in relation to the proposed restructuring. This exclusivity positions Lion Wealth as the sole party with the right to negotiate and advance the restructuring proposal during a six-month period, enabling focused and efficient execution to help Skyfame address its current challenges.

Key Highlights

  • Lion Wealth submitted a restructuring proposal to Skyfame and the joint provisional liquidators on April 7, 2026.
  • Lion Wealth has been granted exclusivity to further negotiations and the entering into of a formal agreement with Skyfame in respect of the proposed restructuring and resumption of trading.
  • Lion Wealth has engaged and is fully supported by a professional team, comprising financial advisers, independent financial advisers, Hong Kong and Bermuda legal counsel, valuers, auditors and other specialists. This professional team is working closely with the joint provisional liquidators to prepare and advance the resumption application to HKEX.

This arrangement highlights LGHL’s commitment to providing structured rescue solutions to distressed listed companies, combining financial support with professional expertise to help maximize value for Skyfame’s stakeholders and facilitate a successful resumption of trading.

Further announcements will be made by LGHL as and when there are material developments regarding the restructuring and resumption process.

About Lion Group Holding Limited:

Lion Group Holding Ltd. (Nasdaq: LGHL) operates an all-in-one, state-of-the-art trading platform that offers a wide spectrum of products and services, including (i) total return swap (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.

Forward-Looking Statements:

This press release contains, “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Lion’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, statements about: Lion’s participation in the restructuring of Skyfame and the potential return/loss from the restructuring; Lion’s goals and strategies; our ability to retain and increase the number of users, members and advertising customers, and expand its service offerings; Lion’s future business development, financial condition and results of operations; expected changes in Lion’s revenues, costs or expenditures; competition in the industry; relevant government policies and regulations relating to our industry; general economic and business conditions globally; proposed crypto asset management operations; and assumptions underlying or related to any of the foregoing. Lion cautions that the foregoing list of factors is not exclusive. Lion cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Lion does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. Additional information concerning these and other factors that may impact our expectations and projections can be found in Lion’s periodic filings with the SEC, including Lion’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024. Lion’s SEC filings are available publicly on the SEC’s website at www.sec.gov.

Contacts

Lion Group Holding Ltd.
Tel: +65 8877 3871
Email: ir@liongrouphl.com

Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026

By
Advertorial Desk
-

Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND

SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ — Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting antibody-drug conjugate (ADC) with a dual-payload platform, at the American Association for Cancer Research Annual Meeting 2026.

The data demonstrate robust antitumor activity across HER2-expressing tumor models, including those with low or heterogeneous HER2 expression and models resistant to prior HER2-targeted therapies and antibody-drug conjugates, including Trastuzumab deruxtecan. These findings support the continued development of TJ106 as a potential treatment option for patients with HER2-expressing cancers who have progressed on existing therapies.

TJ106 is engineered with a biparatopic HER2 antibody designed to bind two distinct epitopes, promoting receptor clustering and enhancing internalization. This approach is intended to improve intracellular delivery of cytotoxic payloads and address limitations associated with heterogeneous HER2 expression and suboptimal uptake observed with earlier HER2-targeted therapies.

The molecule incorporates a dual-payload design combining a topoisomerase I inhibitor and a microtubule inhibitor. These payloads provide complementary and non-overlapping mechanisms of action, enabling sustained cytotoxic activity and the potential to overcome resistance associated with single-payload ADCs. In preclinical studies, TJ106 demonstrated consistent tumor growth inhibition across multiple models, including those previously exposed to HER2-directed therapies.

TJ106 also incorporates an optimized linker system designed to balance plasma stability with efficient intracellular payload release, supporting a favorable therapeutic window in preclinical evaluations.

“The data presented at AACR highlight the potential of TJ106 to address key challenges in HER2-targeted therapy, including resistance and tumor heterogeneity,” said Martin S. Olivo, M.D., M.Sc., Chief Medical Officer of Phrontline Biopharma. “By combining biparatopic targeting with a dual-payload approach, TJ106 is designed to enhance tumor delivery and provide durable antitumor activity while maintaining an acceptable safety profile.”

Phrontline plans to advance TJ106 into IND-enabling studies with an anticipated Investigational New Drug (IND) submission in early 2027. A global Phase I clinical trial is expected to evaluate TJ106 in patients with HER2-expressing solid tumors, including breast and gastric cancers, with a focus on patients previously treated with HER2-targeted therapies, including ADCs. The clinical program is expected to incorporate dose optimization principles aligned with U.S. Food and Drug Administration Project Optimus, including evaluation of exposure–response relationships and multi-cycle tolerability.

⸻

About TJ106

TJ106 is an investigational biparatopic HER2-targeting antibody-drug conjugate (ADC) incorporating a dual-payload platform consisting of a topoisomerase I inhibitor and an eribulin-based microtubule inhibitor. The molecule is designed to enhance tumor targeting, internalization, and intracellular drug delivery to address resistance mechanisms in HER2-expressing cancers.

⸻

About Phrontline Biopharma

Phrontline Biopharma is a clinical-stage oncology company focused on the development of next-generation antibody-drug conjugates (ADCs), including bispecific and dual-payload platforms, to address unmet needs in solid tumors.

⸻

Forward-Looking Statements

This press release contains forward-looking statements regarding TJ106, including anticipated IND timing, clinical development plans, and therapeutic potential. These statements are subject to risks and uncertainties that may cause actual results to differ materially.

J.S. Held Recognizes the Growth of Professionals Across the Firm

By
Advertorial Desk
-

Promotions reflect commitment to expertise, collaboration, and client service excellence. 

NEW YORK, April 14, 2026 /PRNewswire/ — Global consulting firm J.S. Held announces the promotion of hundreds of team members across multiple geographies and areas of expertise, recognizing their achievements and contributions to the firm’s continued growth and client impact. These promotions reflect the firm’s commitment to fostering a culture that values and recognizes specialized knowledge, collaboration, and innovation as it continues to deliver exceptional service and strategic insight to organizations in large and emerging markets.

Executive Perspective

Chief Executive Officer Lee Spirer acknowledges, “J.S. Held was founded on the principle of being a trusted advisor, known for objective and insightful perspectives and ensuring clients are in a position to make well-informed decisions.”  Lee continues, “Today, that founding principle thrives in the hundreds of team members we are proud to promote, each demonstrating the talent, dedication, and integrity our clients rely on.”

Deep Expertise for High-Stakes Engagements

J.S. Held is trusted by clients around the world to respond in moments of crisis, delivering deep technical, scientific, and financial expertise when the stakes are highest.  Across the firm, teams are called upon to investigate failures, assess damage, quantify economic loss, and provide clarity in complex disputes, often in high-stakes legal and insurance settings where findings must withstand rigorous scrutiny.

The firm’s experts conduct technical and financial investigations that address not only physical damage but also the value and integrity of intangible assets, including artificial intelligence and data that enable client products and services. Whether responding to catastrophic events or resolving financial disputes, J.S. Held’s work is grounded in precision, credibility, and real-world impact.

This depth of experience in reactive engagements directly informs the firm’s ability to guide clients proactively. J.S. Held’s deep understanding of how and why things go wrong, along with the financial and operational consequences that follow, enables the firm to help organizations anticipate risk, improve governance, and build long-term resilience. Advisors draw on courtroom-tested insights to deliver forward-looking solutions that enhance performance, protect value, and support long-term business sustainability.

Industry Leadership

J.S. Held experts have been engaged in some of the largest, most complex mandates. More than 1500 experts serve as trusted advisors to organizations across six continents, working with:

  • 84% of the Global 200 Law Firms
  • 75% of the Forbes Top 20 Insurance Companies
  • 90% of the NAIC Top 50 Property & Casualty Insurers
  • 71% of Fortune 100 Companies

“From every corner of our business, agile, collaborative, creative, and client-centric teams provide solution-forward advisory to clients across the globe, no matter the scope or complexity of a project, which is reflective of the trusted advisor role we have earned over the last 50 years,” adds Lee. 

Investment in People and Culture

“The team members we recognize today exemplify our core values and are committed to seeking new and innovative ways to serve our clients and advance thought leadership in our industry,” shares Marjan Panah, J.S. Held Chief People Officer. Their promotions underscore J.S. Held’s strong belief that client service and employee engagement are synonymous, as the firm remains committed to providing a first-class work environment and cultivating a sense of community among its team. J.S. Held recognizes the importance of expert development at all levels within the organization as central to delivering the best solutions for clients.

About J.S. Held

J.S. Held is a global consulting firm that combines technical, scientific, financial, and strategic expertise to advise clients seeking to realize value and mitigate risk. Our professionals serve as trusted advisors to organizations facing high stakes matters demanding urgent attention, staunch integrity, proven experience, clear-cut analysis, and an understanding of both tangible and intangible assets. The firm provides a comprehensive suite of services, products, and data that enable clients to navigate complex, contentious, and often catastrophic situations.

J.S. Held, its affiliates and subsidiaries are not certified public accounting firm(s) and do not provide audit, attest, or any other public accounting services. J.S. Held is not a law firm and does not provide legal advice.  Securities offered through PM Securities, LLC, d/b/a Phoenix IB or Ocean Tomo Investments, a part of J.S. Held, member FINRA/SIPC.  All rights reserved.

Contact:

Kristi L. Stathis | Global Public Relations | +1 786 833 4864 | Kristi.Stathis@jsheld.com

 

NYSE Content Update: OpenLoop Health Debuts At-Home Sleep Apnea Test with 98% Accuracy

By
Advertorial Desk
-

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, April 14, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

Gold medalists to open markets after the Milan Winter Games.

Kristen Scholer delivers the pre-market update on April 14th

  • Equities are little changed Tuesday morning after the S&P 500 gained 1% yesterday and is clinging to optimism for a longer-term ceasefire in the Middle East.  
  • OpenLoop Health CEO Dr. Jon Lensing will join NYSE Live this morning to discuss the company’s expansion into sleep diagnostics in partnership with Happy Sleep.
  • Gold medalists Breezy Johnson and Kate Delson will deliver remarks, ring the Opening Bell, and speak to Kristen Scholer after markets open this morning.
  • IonQ (NYSE: IONQ) Chairman and CEO Niccolo de Masi will celebrate World Quantum Day at the NYSE and join Taking Stock this afternoon.

Opening Bell
Olympic Gold Medalist Breezy Johnson and Paralympic Gold Medalist Kate Delson ring the Opening Bell

Closing Bell
IonQ (NYSE: IONQ) celebrates World Quantum Day

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

Diversified Energy Company CEO Rusty Hutson, Jr. rang the bell.
Diversified Energy Company CEO Rusty Hutson, Jr. rang the bell.

 

 

 

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

By
Advertorial Desk
-

SYDNEY, April 14, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.

The Agreement relates to Nucleus RadioPharma’s state-of-the-art facility in Rochester, Minnesota, which is capable of manufacturing around 50,000 patient doses per year, and future production in Spring House, Pennsylvania. The Spring House facility is a 47,000 square foot site that is planned to open in 2028, enabling broad coverage across the northeast of the US with up to 600,000 doses of 64Cu-SAR-bisPSMA per year. Together, these two facilities in Minnesota and Pennsylvania will provide access to key commercial markets with manufacturing and distribution to all 50 states in the US and select international sites, including Europe.

The Commercial Manufacturing Agreement further builds on Clarity’s existing partnership with Nucleus RadioPharma with a Master Services Agreement and 67Cu-SAR-bisPSMA Clinical Supply Agreement in place from November 20241, covering the existing site in Rochester with additional facilities in Pennsylvania2 and future strategic sites to expand patient access.

This Agreement represents an important step in Clarity’s continued build out of its manufacturing capabilities ahead of 64Cu-SAR-bisPSMA’s anticipated commercial launch upon successful completion of Phase III registrational trials with this product, AMPLIFY3 and CLARIFY4, and subsequent US Food and Drug Administration (FDA) New Drug Application (NDA) approval.

Geoffrey Johnson, MD, PhD, Chief Scientific Officer of Nucleus RadioPharma, commented, “Nucleus RadioPharma is excited to produce a next-generation diagnostic imaging agent, 64Cu-SAR-bisPSMA, that data shows is capable of visualising tiny prostate cancer lesions that the current standard of care prostate specific membrane antigen (PSMA) positron emission tomography (PET) fails to detect. Earlier cancer detection and better cancer staging directly affects patient management and treatment outcomes and I firmly believe that seeing is saving. At Nucleus RadioPharma, we are proud to be driving demonstrable advances at the cutting edge of theranostics.”

Stephen Hahn, MD, Chief Executive Officer of Nucleus RadioPharma, commented, “We are pleased to continue growing our partnership with Clarity through this new Commercial Manufacturing Agreement. At Nucleus RadioPharma, we share Clarity’s goal of improving treatment outcomes for patients with cancer and look forward to delivering novel products to people in need of better diagnostic and therapeutic options. 64Cu-SAR-bisPSMA is now quickly approaching its market launch, and with recently released data highlighting its detection benefits in comparison to standard of care PSMA PET, we could not be more excited about being part of the change in shaping the future of prostate cancer diagnostics.”

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented, “Clarity is building a strong foundation with its supply and manufacturing strategy to support a large-scale commercial rollout of 64Cu-SAR-bisPSMA from day one, with capability to supply not only the entire existing PSMA PET market, but a larger pool of patients that could benefit from our optimised product, given the promising data we have seen in the clinic to date. With large-scale drug product manufacturing, reinforced by large-scale copper-64 production, we will be able to provide 64Cu-SAR-bisPSMA on demand through centralised manufacturing and distribution, broadly with sites servicing the entirety of the US and beyond, including sites close to areas of high demand. The half-life of copper-64 gives us the freedom to deliver a number of models in order to meet the future demand for our products.

“Together with Clarity’s existing copper-64 supply agreements with SpectronRx, Nusano and Theragenics, as well as a 64Cu-SAR-bisPSMA commercial manufacturing agreement with SpectronRx, the new Agreement with Nucleus RadioPharma further enhances Clarity’s broad network of high-volume production in distinct US geographies, building a tiered approach with regional distribution. The network is designed to support commercial-scale demand with secure, seamless and abundant supply and manufacturing.

“Nucleus RadioPharma is a trusted partner with extensive expertise in radiopharmaceuticals across not only the supply and manufacturing side, but also with a unique insight into the impact that radiopharmaceuticals can have on the healthcare system, treating clinicians and their patients. We look forward to continuing to work with their team as we continue to deliver on our promise of improving treatment outcomes for patients with cancer.”

The Commercial Manufacturing Supply Agreement is effective as of 14 April 2026. Cancellation and extension provisions are aligned with industry standard rates.

Disclaimer

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products. Their safety and efficacy have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Nucleus RadioPharma

Nucleus RadioPharma is an innovative CDMO in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, the company provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Nucleus RadioPharma’s technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Recognized for its flexible approach, the company offers multiple onboarding points to accommodate innovators at various stages of their product lifecycle. Backed by Eclipse, Mayo Clinic, AstraZeneca, GE HealthCare, Echo Global, Fox Chase Cancer Center, Granger Management, Mercy Health, and University of Missouri, Nucleus RadioPharma stands well-supported by leading institutions and organizations committed to advancing healthcare through innovative solutions.
Please visit nucleusrad.com and follow on LinkedIn for more information.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.
www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor    

Lisa Sadetskaya

Executive Chairperson 

Director, Corporate Communications

ataylor@claritypharm.com     

lisa@claritypharm.com

References

  1. Clarity Pharmaceuticals. Clarity and Nucleus RadioPharma sign Master Services Agreement and Cu-67 SAR-bisPSMA Clinical Supply Agreement. https://www.claritypharmaceuticals.com/news/nucleus/
  2. Nucleus RadioPharma Expands Radiopharmaceutical Research, Development and Manufacturing Capacity, Addressing Nationwide Supply Chain Constraints, BusinessWire, 21 October 2024, https://www.businesswire.com/news/home/20241021820034/en/Nucleus-RadioPharma-Expands-Radiopharmaceutical-Research-Development-and-Manufacturing-Capacity-Addressing-Nationwide-Supply-Chain-Constraints
  3. ClinicalTrials.gov Identifier: NCT06970847. https://clinicaltrials.gov/study/NCT06970847
  4. ClinicalTrials.gov Identifier: NCT06056830. https://clinicaltrials.gov/study/NCT06056830

This announcement has been authorised for release by the Executive Chairperson.

Apkudo and Qates Launch High-Volume Automated Screen Restoration System to Maximize Device Resale Value

By
Advertorial Desk
-

New Powered by Apkudo technology for buff and polish combines advanced plasma treatment and precision automation to accelerate screen restoration at scale for global refurbishment leaders.

BALTIMORE, April 14, 2026 /PRNewswire/ — Apkudo, the Device Passport™ Platform company, today announced that Qates joined the Powered by Apkudo ecosystem, with the launch of the Apkudo Buff-Polish system. This industrial-grade screen restoration solution is designed for high-volume device processors, carriers, and original equipment manufacturers seeking to maximize the resale value of pre-owned assets. By integrating Qates’ specialized hardware with the Apkudo platform, customers unlock a scalable way to turn scratched screens into like-new, revenue-ready devices.

Qates Powered by Apkudo Buff-Polish Product Image
Qates Powered by Apkudo Buff-Polish Product Image

Cosmetic condition, particularly screen quality, is one of the strongest predictors of resale value in the secondary device market, with scratched displays often triggering double-digit price reductions or costly replacements. Traditional refurbishment often requires costly screen replacements or manual polishing processes that are difficult to scale and frequently lead to inconsistent quality and lower margins for high-volume operators. As consumer demand for pristine used devices increases, the industry needs a repeatable, data-driven method to restore screens without compromising device integrity.

The Qates system offers an easy-to-scale, automated solution that restores screens to a high-quality finish while protecting the device’s original display. This efficient process removes scratches more effectively than traditional methods without the mess or complicated setup usually required for restoration. Each system can handle 12 devices per hour, often enabling businesses to more than double their typical output with a small team. Unlike standalone cosmetic restoration tools, every Buff-Polish action is automatically recorded in the Apkudo Device Passport, creating a permanent, auditable record of improvement that travels with the device across owners, channels, and markets.

“As part of the Powered by Apkudo ecosystem, the Qates system connects physical restoration with digital verification, turning cosmetic improvements into durable, market-recognized value,” said Josh Matthews, CEO and Co-Founder of Apkudo. “This is not just about polishing glass; it is about using data and precision to unlock the full financial and circular potential of every asset.”

Strategic Benefits for Asset Owners

  • Higher residual value: Eliminate scratches that directly reduce resale prices
  • Lower refurbishment cost: Avoid unnecessary screen replacements
  • Verified trust: Every improvement recorded in the Device Passport
  • Operational scale: High throughput without expanding facility footprint
  • Sustainable growth: Extend device lifespan and reduce parts dependency

Learn more about Apkudo’s Device Passport platform and the new Buff-Polish solution by visiting apkudo.com. 

About Apkudo
Apkudo is the Device Passport Platform for the connected device ecosystem. We capture and unify data from every program, transaction, and touchpoint across a device’s lifecycle, creating a single, trusted Device Passport™ for every asset. For companies that manage, sell, or buy devices, this means a verified record they can act on: to restore buyer confidence, maximize value, and reduce risk at every decision point. Our unique advantage is data fidelity and veracity, built on precision-automated robotics that have processed millions of devices, generating objective, machine-verified data that no competitor can match. To learn more, visit apkudo.com.

Media Contact:
Kristen Barry
SVP Marketing and Communications
kristen.barry@apkudo.com

 

Hesai Powers Safety-Certified AI Autonomy for Smart Logistics with 3D Lidar at MODEX 2026

By
Advertorial Desk
-

PALO ALTO, Calif., April 14, 2026 /PRNewswire/ — Hesai Technology (NASDAQ: HSAI; HKEX: 2525), a global leader in lidar solutions, attended MODEX 2026 in Atlanta, showcasing its latest 3D lidar solutions for smart logistics applications. At the event, Hesai highlighted its collaboration with Thoro.ai, a Pittsburgh-based, industry-leading robotics company. Hesai will supply its high-performance mini 3D lidar, the JT128, to power Thoro.ai’s perception platform across a wide range of robotic applications, including the industry’s first safety-certified AI autonomy platform for industrial and commercial robots.

Hesai Powers Safety-Certified AI Autonomy for Smart Logistics with 3D Lidar at MODEX 2026
Hesai Powers Safety-Certified AI Autonomy for Smart Logistics with 3D Lidar at MODEX 2026

Thoro.ai is a software-first robotics company dedicated to enabling OEMs to launch safety-certified autonomous solutions with minimal in-house development. Through CoreFlex — a unified sensor and software suite — OEMs can accelerate time to market, reduce costs, and scale a single autonomy solution across multiple robot types. High-performance sensors like Hesai’s JT128 are critical to making this versatile architecture a reality, providing reliable data that can be used consistently across different machines and applications.

Hesai’s collaboration with Thoro.ai has already begun with significant developments underway. Four new autonomous mobile robots slated for release next year will all be powered by the JT128 lidar. Designed for various workflows across cleaning and material handling, this integration highlights the scalability of CoreFlex and the JT128’s ability to accelerate a wide range of autonomous applications.

With its slim 30 mm window height and a 70% smaller volume compared to similar products, the JT128 can be easily integrated into machines of all sizes, from small cleaning robots to large industrial robots. Its compact form factor helps Thoro.ai streamline hardware integration and simplify development, enabling OEM partners to adopt autonomy faster.

In addition to its compact size, the JT128 features the world’s widest 360° × 187° ultra-hemispherical field of view, delivering all-around perception coverage with no blind spots. In warehouse environments, some of Thoro.ai’s robots require vertical awareness to detect objects beneath forks and align with rack beams above. The vertical field of view of the JT128 enables true autonomous pallet handling while meeting strict safety standards.

Because lidar actively emits laser light, it is not affected by ambient lighting conditions. This makes the JT128 highly reliable across all of Thoro.ai’s robotic applications, including challenging environments with reflective surfaces and glass.

“At Thoro.ai, we think about each of these OEM partnerships not just as standalone projects, but as part of our CoreFlex autonomy architecture: a modular, safety-certified platform designed to scale across many machine types,” says Patrick Mondi, CEO of Thoro.ai. “The JT series plays a key role in making that possible by giving us reliable, high-fidelity perception that works consistently across very different form factors. This simplifies the integration process for our partners, lowers their development costs, and gets their autonomous solutions to market faster. Hesai’s responsiveness, bug testing, and rapid iteration cycles also align directly with our mission to deliver safe, reliable autonomy at scale.”

The collaboration between Hesai and Thoro.ai marks a significant step forward in the robotics industry. By integrating Thoro.ai’s advanced AI-driven autonomy software with Hesai’s high-performance JT128 lidar, the two companies are enabling OEMs to launch autonomous mobile robots that are safer, more intelligent, and faster to deploy. Visitors are invited to stop by Hesai’s booth (Hall A #5306) at MODEX 2026 to see firsthand how the company’s latest innovations are shaping the future of smart logistics.

Aramco Stadium Company announces executive leadership appointments

By
Advertorial Desk
-

DHAHRAN, Saudi Arabia, April 14, 2026 /PRNewswire/ — Aramco Stadium Company, a subsidiary of Aramco, today announced its official launch and the appointment of its inaugural Board of Directors and Chief Executive Officer. The appointments mark a key milestone in activating the company and delivering one of the Kingdom’s most important sports and entertainment development projects, aligning with Saudi Arabia’s Vision 2030 and contributing to its hosting of the 2034 FIFA World Cup.

Aramco Stadium
Aramco Stadium

 

Fahad Al Dhubaib has been appointed Chairman of the Board of Directors of Aramco Stadium Company, and Mohammed Al Thomairi has been appointed Vice Chairman of the Board. Abdulrahman Alqudaib, Bader Alreziza, Nader Ashoor, Jefferson Slack, and James Bisgrove have also been appointed as Board members. In addition, Matthew Kittle has been named CEO. The board members and executive leadership possess extensive experience and skills in global sports and entertainment development, the management of major facilities and events, and commercial development and financial sustainability.

Located in Al-Khobar, Aramco Stadium is set to open this year with a capacity of 47,000 seats, and it will serve as the home ground for Al-Qadsiah Football Club. The stadium is part of an integrated complex spanning 800,000 square meters designed to welcome local residents and visitors from around the world throughout the year. The stadium is also intended to host international competitions, including the AFC Asian Cup 2027 and the FIFA World Cup 2034, as well as other entertainment events, further strengthening its role in the evolving sports and entertainment landscape of the Kingdom.

Aramco Stadium Company Contact Information

https://www.aramcostadium.com/en

Media Contacts:

Aramco Stadium Public Relations Team
pr@aramcostadium.com

About Aramco Stadium

Aramco Stadium is a state-of-the-art, multi-purpose sports and entertainment venue in Saudi Arabia’s Eastern Province, set within an 800,000+ square meter campus designed as a year-round destination. Built to international tournament standards, the fully air-conditioned stadium is intended to host matches during the 2027 AFC Asian Cup and the 2034 FIFA World Cup, underscoring its leadership within the Kingdom’s expanding global sports portfolio and its alignment with Saudi Vision 2030. Home to Al-Qadsiah FC, Aramco Stadium integrates advanced venue technology and premium hospitality to deliver world-class experiences while anchoring a fence-free campus featuring restaurants, nearly 130,000 square meters of public park space, sports courts, playgrounds, and community programming, establishing a vibrant 365-day destination for residents and international visitors alike.

1...566567568...6,503Page 567 of 6,503